KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Enterprise Value (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Enterprise Value for 18 consecutive years, with -$3.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value fell 14.64% year-over-year to -$3.0 billion; the TTM value through Mar 2026 reached -$3.0 billion, down 14.64%, while the annual FY2025 figure was -$2.9 billion, 197.75% down from the prior year.
  • Enterprise Value hit -$3.0 billion in Q1 2026 for Alnylam Pharmaceuticals, down from -$2.9 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$606.5 million in Q2 2022 and bottomed at -$3.0 billion in Q1 2026.
  • Average Enterprise Value over 5 years is -$1.8 billion, with a median of -$2.0 billion recorded in 2023.
  • On a YoY basis, Enterprise Value climbed as much as 67.17% in 2022 and fell as far as 405.73% in 2022.
  • Alnylam Pharmaceuticals' Enterprise Value stood at -$896.7 million in 2022, then crashed by 170.8% to -$2.4 billion in 2023, then skyrocketed by 59.77% to -$976.8 million in 2024, then crashed by 197.75% to -$2.9 billion in 2025, then decreased by 3.46% to -$3.0 billion in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$3.0 billion, -$2.9 billion, and -$2.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.